We conclude that plasma p-tau217 and tau-PET showed similar associations with future cognitive decline in a CU population, that both tau biomarkers provide complementary information and that their sequential use (that is, plasma p-tau217 followed by tau-PET in a subset with high plasma p-tau217) is useful for screening in clinical trials in preclinical AD. This evidence concerns the gene MAPT and Alzheimer disease.